首页> 外文期刊>Modern Pathology >Primary retroperitoneal myxoid|[sol]|round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis
【24h】

Primary retroperitoneal myxoid|[sol]|round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis

机译:原发性腹膜后黏液样| [sol] |圆形细胞脂肪肉瘤是不存在的疾病:免疫组织化学和分子生物学分析

获取原文
           

摘要

Almost all primary retroperitoneal liposarcomas can be classified as well-/dedifferentiated liposarcoma. Rarely, however, primary retroperitoneal liposarcoma is classified as myxoid/round cell liposarcoma, based on the presence of myxoid areas and vascular crow's feet pattern, which has resulted in a debate on the classification of liposarcoma in the retroperitoneum. Genetically, myxoid/round cell liposarcoma and well-/dedifferentiated liposarcoma are different diseases. Myxoid/round cell liposarcoma is characterized by a translocation causing FUS-CHOP or EWSR1-CHOP fusion, whereas well-/dedifferentiated liposarcoma is characterized by an amplification of the 12q13-15 region, including MDM2 and CDK4 genes. As myxoid/round cell liposarcoma is highly radio- and chemosensitive, differentiation between subtypes is important to optimize treatment. We studied whether primary retroperitoneal liposarcomas diagnosed as myxoid/round cell liposarcoma represent molecularly true myxoid/round cell liposarcoma or are histopathological mimics and represent well-/dedifferentiated liposarcoma. Primary retroperitoneal myxoid/round cell liposarcoma (n=16) were compared to primary extremity myxoid/round cell liposarcoma (n=20). Histopathological and immunohistochemical features were studied. Amplification status of the 12q13-15 region was studied using a multiplex ligation-dependent probe amplification analysis, and FUS-CHOP or EWS-CHOP translocations were studied using RT-PCR. In primary retroperitoneal myxoid/round cell liposarcoma, MDM2 and CDK4 staining was both positive in 12 of 15 cases. In primary extremity myxoid/round cell liposarcoma, MDM2 was negative in 18/20 and CDK4 was negative in all cases. Multiplex ligation-dependent probe amplification showed the amplification of 12q13-15 region in 16/16 primary retroperitoneal myxoid/round cell liposarcomas and in 1/20 primary extremity myxoid/round cell liposarcomas. Translocation was present in all (18/18) primary extremity myxoid/round cell liposarcomas, but absent in all primary retroperitoneal myxoid/round cell liposarcomas. On the basis of immunohistochemical and molecular characteristics, apparent primary retroperitoneal myxoid/round cell liposarcoma can be recognized as well-/dedifferentiated liposarcoma with morphological features mimicking myxoid/round cell liposarcoma. In these cases, treatment should probably be specifically designed as for well-/dedifferentiated liposarcoma. Moreover, finding of myxoid/round cell liposarcoma translocations in a retroperitoneal localization is highly suggestive of metastasis and should prompt search for a primary localization outside the retroperitoneum.
机译:几乎所有的原发性腹膜后脂肪肉瘤都可以归为高度分化/去分化的脂肪肉瘤。然而,基于粘液样区域和血管鱼尾纹的存在,原发性腹膜后脂肪肉瘤很少被分类为粘液样/圆形细胞脂肪肉瘤,这引起了关于腹膜后脂肪肉瘤分类的争论。从基因上讲,粘液样/圆形细胞脂肪肉瘤和高度分化/去分化的脂肪肉瘤是不同的疾病。粘液样/圆形细胞脂肪肉瘤的特征是易位,引起FUS-CHOP或EWSR1-CHOP融合,而分化良好的脂肪肉瘤的特征是12q13-15区域的扩增,包括MDM2和CDK4基因。由于粘液样/圆形细胞脂肪肉瘤具有高度的放射敏感性和化学敏感性,因此亚型之间的区分对于优化治疗很重要。我们研究了诊断为粘液样/圆形细胞脂肪肉瘤的原发性腹膜后脂肪肉瘤是分子上真正的粘液样/圆形细胞脂肪肉瘤还是组织病理学模拟物,并且代表了分化良好/去分化的脂肪肉瘤。将原发性腹膜后粘液样/圆形细胞脂肪肉瘤(n = 16)与原发性肢端粘液样/圆形细胞脂肪肉瘤(n = 20)进行比较。研究了组织病理学和免疫组化特征。使用多重连接依赖性探针扩增分析研究了12q13-15区域的扩增状态,并使用RT-PCR研究了FUS-CHOP或EWS-CHOP易位。在原发性腹膜后粘液样/圆形细胞脂肪肉瘤中,15例中的12例MDM2和CDK4染色均为阳性。在原发性粘液样/圆形细胞脂肪肉瘤中,MDM2在所有情况下均为18/20阴性,而CDK4在所有情况下均为阴性。多重连接依赖性探针扩增显示16/16原发性腹膜后粘液样/圆形细胞脂肪肉瘤和1/20原发性肢体粘液样/圆形细胞脂肪肉瘤中12q13-15区域的扩增。在所有(18/18)原发性四肢粘液样/圆形细胞脂肪肉瘤中均存在易位,但在所有原发性腹膜后粘液样/圆形细胞脂肪肉瘤中均不存在易位。根据免疫组织化学和分子特征,明显的原发性腹膜后粘液样/圆形细胞脂肪肉瘤可被认为是具有良好形态/去分化的脂肪肉瘤,其形态学特征类似于粘液样/圆形细胞脂肪肉瘤。在这些情况下,应该针对分化良好的脂肪肉瘤专门设计治疗方法。此外,在腹膜后定位中发现类固醇/圆形细胞脂肪肉瘤易位,高度提示转移,应提示在腹膜后以外寻找主要定位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号